The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects

被引：181

作者：

Maeng S. ^{[1
]}

Zarate Jr. C.A. ^{[1
]}

机构：

[1] Bethesda, MD 20892

来源：

Current Psychiatry Reports | 2007年 / 9卷 / 6期

基金：

美国国家卫生研究院;

关键词：

NMDA; Ketamine; NMDA Receptor; Mood Disorder; Memantine;

D O I：

10.1007/s11920-007-0063-1

中图分类号：

学科分类号：

摘要：

In this article, we first review a study showing that the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine leads to rapid, robust, and relatively sustained antidepressant effects in patients with treatment-resistant major depression. We then discuss our hypothesis that the therapeutic effects of monoaminergic antidepressants and ketamine may be mediated by increased AMPA-to-NMDA glutamate receptor throughput in critical neuronal circuits. We hypothesize that ketamine directly mediates this throughput, whereas monoaminergic antidepressants work indirectly and gradually; this may explain, in part, the lag of onset of several weeks to months that is observed with traditional antidepressants. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：467 / 474

页数：7

共 57 条

[1]

Fagiolini A., Kupfer D.J., Masalehdan A., Et al., Functional impairment in the remission phase of bipolar disorder, Bipolar Disord, 7, pp. 281-285, (2005)

[2]

Huxley N., Baldessarini R.J., Disability and its treatment in bipolar disorder patients, Bipolar Disord, 9, pp. 183-196, (2007)

[3]

Rush A.J., Trivedi M.H., Wisniewski S.R., Et al., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report, Am J Psychiatry, 163, pp. 1905-1917, (2006)

[4]

Trivedi M.H., Rush A.J., Wisniewski S.R., Et al., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice, Am J Psychiatry, 163, pp. 28-40, (2006)

[5]

Manji H.K., Moore G.J., Rajkowska G., Chen G., Neuroplasticity and cellular resilience in mood disorders, Mol Psychiatry, 5, pp. 578-593, (2000)

[6]

Payne J.L., Quiroz J.A., Zarate Jr C.A., Manji H.K., Timing is everything: Does the robust upregulation of norad-renergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation?, Biol Psychiatry, 52, pp. 921-926, (2002)

[7]

Zarate Jr C.A., Singh J., Manji H.K., Cellular plasticity cascades: Targets for the development of novel therapeutics for bipolar disorder, Biol Psychiatry, 59, pp. 1006-1020, (2006)

[8]

Sanacora G., Rothman D.L., Mason G., Krystal J.H., Clinical studies implementing glutamate neurotransmission in mood disorders, Ann N Y Acad Sci, 1003, pp. 292-308, (2003)

[9]

Zarate Jr C.A., Du J., Quiroz J., Et al., Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: Role of the glutamatergic system, Ann N Y Acad Sci, 1003, pp. 273-291, (2003)

[10]

Zarate C.A., Quiroz J., Payne J., Manji H.K., Modulators of the glutamatergic system: Implications for the development of improved therapeutics in mood disorders, Psychopharmacol Bull, 36, pp. 35-83, (2002)

← 1 2 3 4 5 6 →